[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/en\/article\/modal\/10871\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n 1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n 2) Linking back to our original story\u003Cbr \/\u003E\n 3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n \n\u003Cdiv\u003E\n \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003ETackling heart disease and stroke risks with customised treatment\u003C\/h2\u003E\u003Cp\u003EProfessor Rick Grobbee believes the key to better treatment for individual patients with heart disease is to look at large numbers of them. This approach can reveal different subgroups of disease.\u003C\/p\u003E\u003Cp\u003EGrobbee, a researcher at University Medical Center Utrecht in the Netherlands, was so intrigued by this potential that he made it the focus of his work after studying high blood pressure in the early 1980s.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EPatient populations\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018That really made me switch my career,\u2019 Grobbee said. \u2018I found it extremely exciting and rewarding to study patient populations.\u2019\u003C\/p\u003E\u003Cp\u003EMore recently, he channelled his expertise into a ground-breaking research project that received EU funding to collect information on patients with heart conditions. Called\u0026nbsp;\u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/id\/116074\u0022\u003EBigData@Heart\u003C\/a\u003E, the project ended in February 2023 after six years.\u003C\/p\u003E\u003Cp\u003EHeart disease is so widespread in Europe that the pool of patients from whom to collect data is large.\u003C\/p\u003E\u003Cp\u003EIn 2015, more than 85 million people in Europe were living with cardiovascular disease, according to the European Heart Network.\u003C\/p\u003E\u003Cp\u003EPeople across the continent enter hospitals every day with chest pains, nausea and shortness of breath \u2013 a few of the indications of a heart attack. Warning signs can exist for weeks or attacks can be sudden.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ENo matter why patients turn up, their arrival is often the end stage of an illness in development for some time.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u2018Heart failure is very disabling,\u2019 said Grobbee. \u2018It has a major impact on people\u2019s quality of life.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EUnderlying illnesses\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EHeart disease accounts for 45% of all deaths in Europe.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EBehind heart failures and heart attacks lie different illnesses. Treatments work for some and not for others.\u003C\/p\u003E\u003Cp\u003E\u2018The problem is that, in heart failure and heart disease, we have a lot of medications but we often treat everyone the same way,\u2019 said Grobbee. \u2018That is probably not the best approach.\u2019\u003C\/p\u003E\u003Cp\u003ELarge numbers of people don\u2019t respond to treatment, some show little improvement and still others face side effects.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EBigData@Heart, which Grobbee led, brought together information from 50 million patients with heart conditions using databases, machine learning and artificial intelligence.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EScale and history\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003EIn heart failure and heart disease, we have a lot of medications but we often treat everyone the same way.\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EProfessor Rick Grobbee, BigData@Heart\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003E\u2018That\u2019s such a big scale that it creates an opportunity to delve much deeper into this diversity,\u2019 he said. \u2018Combined with computer power, it allows us to look much further away \u2013 like how a telescope allows you to look at stars that are otherwise invisible.\u2019\u003C\/p\u003E\u003Cp\u003EThis approach has a history. In 1948, the \u201cFramingham Heart Study\u201d began in the US state of Massachusetts and continues to this day. It has revealed that factors such as high blood pressure, elevated cholesterol levels, diet and lifestyles greatly influence the risk of heart attack.\u003C\/p\u003E\u003Cp\u003EThis ushered in a treatment revolution, with targeted drugs for high blood pressure saving millions of lives.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EIn BigData@Heart, Grobbee and his colleagues sought to repeat this feat by better understanding patient subgroups.\u003C\/p\u003E\u003Cp\u003EPatients were classified more narrowly according to whether they had other conditions such as diabetes, kidney troubles or heart-rhythm disorders. Doctors could then see which treatments worked best for which subgroups.\u003C\/p\u003E\u003Cp\u003EThe research featured specialist organisations in six EU countries \u2013 Belgium, France, Germany, the Netherlands, Spain and Sweden \u2013 and in Switzerland, the UK and the US.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ECustomised cures\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EThe project made gains.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EFor beta blockers, which are medications that reduce blood pressure, the statistics revealed that some patients benefit, some don\u2019t and a third group suffers side effects.\u003C\/p\u003E\u003Cp\u003EAs a result, doctors will start off better equipped to assess patients, even if the precise medical condition of any one of them is atypical.\u003C\/p\u003E\u003Cp\u003E\u2018Now physicians can use that information to better customise and tweak treatments,\u2019 said Grobbee. \u2018We learned from large numbers to give better guidance for individual patients.\u2019\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EBigData@Heart had industry involvement built in. As a part of an EU public-private research partnership called the \u003Ca href=\u0022https:\/\/www.ihi.europa.eu\/\u0022\u003EInnovative Medicines Initiative\u003C\/a\u003E, the project included the pharmaceutical industry, which contributed funding and its own own studies.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u2018It was great to work with them because of their ability to look at different types of patients who might benefit from therapies so we can repurpose drugs or design new ones,\u2019 said Dipak Kotecha, a professor of cardiology at the University of Birmingham in the UK and a project participant.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ENeck arteries\u0026nbsp;\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EAnother EU-funded research project is taking a broadly similar approach to tackle a different medical challenge: strokes.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003EIf you have problems in your carotid arteries, then you might have problems in your brain.\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EProfessor Dimitrios Fotiadis, TAXINOMISIS\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003ECalled\u0026nbsp;\u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/id\/755320\u0022\u003ETAXINOMISIS\u003C\/a\u003E, the initiative is categorising patients by using medical imaging, blood-test results and existing health conditions. Due to wrap up in December 2023 after six years, it too harnesses the power of AI and advances the idea of personalised medicine.\u003C\/p\u003E\u003Cp\u003EThe focus has been on a disease affecting two arteries in the neck that supply blood to the brain. They\u2019re called carotid arteries.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EWith carotid artery disease, deposits called plaques build up there. This can narrow the passageway for blood or cause pieces of plaque to break off and flow into the brain.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u2018If you have problems in your carotid arteries, then you might have problems in your brain,\u2019 said Dimitrios Fotiadis, who leads TAXINOMISIS and is a professor of biomedical engineering at the University of Ioannina in Greece.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ESuch brain illnesses include stroke and dementia. An estimated 30% of strokes involve carotid artery disease, underlying the push to discover plaques and intervene.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EDislodged-plaque risks\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EAt present, patients are assessed with medical imaging such as MRI to estimate how much blockage is present.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EBut this technique is imperfect. There are different types of plaques, some more likely to break off.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ETAXINOMISIS developed software that generates a 3-D image of the artery and predicts whether the plaque will expand and the risks of it breaking up and damaging the brain.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThis lets the doctor decide whether a patient can go home, be prescribed a drug or receive a stent \u2013 a thin, hollow tube that is surgically inserted to expand a narrowing artery.\u003C\/p\u003E\u003Cp\u003EAlternatively, a person\u2019s risk assessment could suggest that surgery is needed.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EDoctors in Greece, Germany, the Netherlands, Serbia and Spain have been putting the tool through its paces with 300 patients and offering feedback to the developers.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EBetter test\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EAnother part of the project designed a \u201clab on a chip\u201d \u2013 a technology that with a drop of blood tests for a handful of genes implicated in carotid artery disease. This technique can give results in minutes rather than hours, significantly reducing costs.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EFotiadis estimates it takes four to six years to bring a completed prototype to the market.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EIn any case, he said the ultimate benefit of research such as TAXINOMISIS is that it will give doctors a better perspective about the particular needs of an individual patient.\u003C\/p\u003E\u003Cp\u003E\u2018The doctor ultimately decides about the treatment,\u2019 said Fotiadis.\u003C\/p\u003E\u003Cp\u003EGrobbee in Utrecht echoed the point.\u003C\/p\u003E\u003Cp\u003E\u2018For doctors, this all helps make sense of some of the confusion as to why our patients sometimes respond so differently,\u2019 he said.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EResearch in this article was funded by the EU. The views of the interviewees don\u2019t necessarily reflect those of the European Commission. If you liked this article, please consider sharing it on social media\u003C\/em\u003E.\u003C\/p\u003E\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n Please copy the above code and embed it onto your website to republish.\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-p9ymc6sihsddhqgg9cdp5lfjivytgqeh91te7tqgfme\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-P9yMc6SIHsDDhQgG9cDP5lfjIvYTGqeH91tE7TqGfmE\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]